309 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words
6-K
EX-99.1
ogj6apq1b0k
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
ungh c8rtaf
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-10.1
grbfjqfb 16
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-99.1
u7f l6zt651
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
5pf82
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
qz74jg0j5 3h5
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
EX-2.1
4at udfk9
26 Mar 24
Annual report (foreign) (amended)
4:57pm
20-F/A
4k3zk g6a6lxw5
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
5k84e4w0rtnh9a8ns xk
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
svvr4129
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
8aza4ywn 0f3o8fwx
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
m81xxv7b8osy6zup ph
16 Feb 24
Current report (foreign)
7:07am
F-3
tuumf33ik afcmz
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
vpo57ywn9
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am